维普期刊资源整合服务平台（V6.5）

70篇 您的检索式：作者名="Eder JP"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	Novel therapeutic inhibitors of the c-Met signaling pathway in cancer显示文摘	Eder JP Vande Woude GF Boerner SA	2009	Clin Cancer Res2009，15，7：	1
2	Safety and pharmacokineties of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43 - 9006,in patients with advanced refractory solid tumors显示文摘	Clark JW Eder JP Ryan D	2005	Clin Cancer Res2005，11，：	1
3	Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY439006, in patient with advanced, refractory solid tumor 显示文摘	Clark JW Eder JP Ryan D	2005	Clin Cancer Res2005，11，15：	1
4	A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2显示文摘	Eder JP Shapiro GI Appleman LJ	2010	Clin Cancer Res2010，16，13：	1
5	Phase Ⅰ clinical trial ofihe farnesyl transferase inhibitor BMS-214662 giVen as l-hour intravenous infusion in patients with advanced solid tumors显示文摘	Ryan DP Eder Jr JP Puchlaski T	2004	Clin Cancer Bes2004，10，：	1
6	MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer 显示文摘	Powles T Eder JP Fine GD	2014	Nature2014，515，7528：	1
7	Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily显示文摘	Eder JP Supko JG Clark JW	2002	J Clin Oncol2002，20，18：	1
8	DNA topoisomerase Ⅱ alpha expression is associated with alkylating agent resistance 显示文摘	Eder JP Chan VT Ng SW	1995	Cancer Res1995，55，24：	1
9	MPDL3280A ( anti-PD-L1 ) treatment leads to clinical activity in metastatic bladder cancer 显示文摘	Powles T Eder JP Fine GD	2014	Nature2014，515，7528：	1
10	MPDI3280A ( anti - PD - LI ) treatment leads to clinical activity in metastatic bladder cancer 显示文摘	Powles T Eder JP Fine GD	2014	Nature2014，515，7528：	1
11	Pharmacokinetics of irinotecan and the proteasome inhibitor bortezomib in adult patients with solid malignancies 显示文摘	Supko JG Eder JP Lynch TJ	2003	Proc Am Soc Clin Oncol2003，22，1：	1
12	Novel therapeutic inhibitors of the c-Met signaling pathway in cancer显示文摘	Eder JP Vande Woude GF Boerner SA	2009	Clin Cancer Res2009，15，：	1
13	Phase I clinical trail of recombinant human endostatin administered as a short intravennous infusion repeated daily 显示文摘	Eder JP Supko JG Clark JW	2002	J Clin Oncol2002，20，18：	1
14	Phase I clinical trial of recombinant human endostratin adminsistered as a short intravenousinfusion repeated daily 显示文摘	Eder JP Supko JG Clark JW	2003	J Clin Oncol2003，20，18：	1
15	Novel therapeutic inhibitors of the c-Met signaling pathway in cancer显示文摘	Eder JP Vande Woude GF	2009	Clin Cancer Res2009，15，7：	1
16	Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43 -9006, in patients with advanced, refractory solid tumors显示文摘	Clark JW Eder JP Ryan D	2005	Clin Cancer Res2005，11，15：	1
17	Novel therapeutic inhibitors of the e-Met signaling pathway in cancer显示文摘	Eder JP Vande Woude GF Boerner SA	2009	Clin Cancer Res2009，15，7：	1
18	MpdI3280a ( anti-pd-11 )treatment leads to clinical activity in metastatic bladder cancer显示文摘	Powles T Eder JP Fine GD	2014	Nature2014，515，：	1
19	MPDL3280A(anti-PD-Ll) treatment leads to clinical activity inmetastatic bladder cancer 显示文摘	Powles T Eder JP Fine GD	2014	Nature2014，515，7528：	1
20	Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology显示文摘	Lorusso PM Eder JP	2008	Expert Opin Investig Drugs2008，17，7：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示